S-23
Pharmacology detail: animal ratings
These ratios are not measured human benefit or safety rankings.
This profile covers S-23. Compare the ingredient, formulation and evidence with compounds you already recognize, then read the risks.
Technical catalog description
S-23 is the harsh end of the SARM category. It was investigated partly for male contraceptive potential because it can strongly suppress gonadotropins and spermatogenesis.
Users chase S-23 for dry recomp, hardness, density, and strength drive. It should not be treated as a casual beginner SARM, because suppression and recovery burden can become steroid-like.
Read next
Mechanism details
S-23 is the harsh end of the SARM category. It was investigated partly for male contraceptive potential because it can strongly suppress gonadotropins and spermatogenesis. That alone tells the practical story: S-23 is not a casual beginner SARM. It behaves like a dry, aggressive androgen-receptor drug with recovery consequences that can rival steroid use.
Users chase S-23 for hardness, density, fat-loss support, and strength drive without aromatization. It can produce a sharp, grainy look in the same broad aesthetic family as dry oral steroids. The cost is suppression, irritability in some users, possible cramps or dark urine reports, and the usual research-chemical uncertainty.
S-23 does not provide estrogen. If endogenous testosterone falls hard and no testosterone base is present, low-estrogen symptoms can become part of the run: dry joints, low libido, poor mood, and flat training feel despite the compound’s androgenic push.
Natural suppression with reduced fertility and testicular output
Suppression, worsened lipids, and an evidence base that is much thinner than users assume
CBC / hematocrit
blood pressure
lipid panel
Uncontrolled hypertension or untreated cardiovascular disease
Pre-existing severe infertility concerns unless that risk is accepted and managed
First-cycle or low-experience use
S-23 is chosen by users who already know the SARM category and want something more aggressive than RAD-140 or LGD-4033. It is usually a cutting or recomp drug, not a friendly lean-bulk aid.
The attraction is the ratio of visible effect to scale movement. Users want the look: dry, hard, dense, and stronger in the gym while calories are controlled.
The effect can show within the first couple of weeks as hardness, strength drive, and libido changes. Suppression can also show quickly. Testicular shrinkage and sexual-function changes are not surprising with S-23.
Shorter, tightly observed runs make more sense than casual long exposure. Bloodwork and recovery planning matter more here than with milder SARMs.
The main mistake is thinking “SARM” means “before real compounds.” S-23 can suppress hard enough to create steroid-like recovery problems.
Another mistake is using it without a plan for estrogen support. Dry androgen-receptor activation can still feel awful if testosterone and estradiol collapse underneath it.
Compared with RAD-140, S-23 is usually harsher, drier, and more suppressive.
Compared with LGD-4033, S-23 is less mass-oriented and more aggressive for recomp.
Compared with Trenbolone, S-23 chases a similar dry-recomp idea but does not have tren’s full anabolic potency or progestin profile. It still carries enough downside that the comparison should not make it sound beginner-friendly.